ReviewOpen access Macedonian journal of medical sciences2019
Botulin Toxin Use in Rosacea and Facial Flushing Treatment.
Review in Open access Macedonian journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- The Latest Advances in Rosacea Treatment: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Off-Label Treatment in Inflammatory Skin Diseases-European Point of View.Journal of clinical medicine · 2025Review
- Therapeutic strategies focusing on immune dysregulation and neuroinflammation in rosacea.Frontiers in immunology · 2024Review
- The Mind Body Connection in Dermatologic Conditions: A Literature Review.Journal of cutaneous medicine and surgery · 2023Review
- Subjective and Objective Measurements of the Facial Effects of Microdoses of Botulinum Toxin.Dermatology practical & conceptual · 2023Article
- Rosacea pathogenesis and therapeutics: current treatments and a look at future targets.Frontiers in medicine · 2023Review
- Botulinum Toxin A Alleviates Persistent Erythema and Flushing in Patients with Erythema Telangiectasia Rosacea.Dermatology and therapy · 2022Article
- Botulinum Toxin Use for Modulating Neuroimmune Cutaneous Activity in Psoriasis.Medicina (Kaunas, Lithuania) · 2022Review
- Hydroxocobalamin: An Effective Treatment for Flushing and Persistent Erythema in Rosacea.The Journal of clinical and aesthetic dermatology · 2022Article
- Physicians' Practice of the Non-Cosmetic Uses of Botulinum Toxin: A Cross-Sectional Study in Saudi Arabia.Cureus · 2022Article
- Multifaceted MRGPRX2: New insight into the role of mast cells in health and disease.The Journal of allergy and clinical immunology · 2021Review
- Willingness-to-Pay and Benefit-Cost Analysis of Botulinum Toxin for the Treatment of Rosacea in China: Findings from a Web-Based Survey.Patient preference and adherence · 2021Article
- Role of Botulinum Toxin in the Management of Topical Corticosteroid Induced Rosacea Like Dermatitis: A Case Report.Indian dermatology online journalArticle
- Persistent Facial Blanching after Botulinum Toxin Injection.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum toxin (BTX) is a neurotoxin derived from the Clostridium botulinum bacterium that inhibits the release of acetylcholine at the neuromuscular junction level whose effects has been used for many years to treat a variety of muscular/neuromuscular conditions and more recently also for cosmetic use. BTX has experimented in some dermatological conditions, which include Rosacea and facial flushing treatment with good results. The complex mechanism underlying those results is not completely understood but was proposed a release inhibition of acetylcholine from peripheral autonomic nerves of the cutaneous vasodilatory system combined with the blockade substance P and calcitonin gene-related peptide (CGRP) thus modulating blood vessel dilatation. We analysed the published data on BTX off label applications rosacea and flushing retrieved from PubMed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.